Main clinical variables of the entire study sample at the study run-in (623 patients)
| General data | |
| Age, years | 49±16 |
| Male, % | 69 |
| Age at diagnosis, years | 39±18 |
| NYHA III–IV, % | 6 |
| LVOT obstruction, % | 32 |
| Previous myectomy, % | 6 |
| ICD, % | 12 |
| SCD risk factors | |
| NSVT, n (%) | 214 (34) |
| FH-SCD, n (%) | 71 (11) |
| MWT >30 mm, n (%) | 42 (7) |
| Unexplained syncope, n (%) | 94 (15) |
| ABPRE, n (%) | 114 (18) |
| Echocardiographic data | |
| LVEDd, mm | 46±5 |
| LAd, mm | 42±7 |
| MWT, mm | 20±5 |
| LVOTGmax, mm Hg | 12(7–34) |
| LVEF, % | 63±7 |
| CPET data | |
| ΔSBP, mm Hg | 44±24 |
| Peak HR, % of predicted | 81±14 |
| AT VO2, mL/kg | 14±4 |
| AT VO2, % of predicted | 48±13 |
| Peak VO2, mL/kg/min | 21±7 |
| Peak VO2, % of predicted | 71±20 |
| CP, mL/kg×mm Hg | 3521±1443 |
| CP%, % of predicted×mm Hg | 11 927±4430 |
| VO2/WL slope, mL/W | 11±2 |
| VE/VCO2 slope | 29±6 |
| Medical treatment | |
| β-blocker, % | 67 |
| Verapamil, % | 9 |
| Dysopiramide, % | 4 |
| ACE-I/ARB, % | 26 |
| Diuretics, % | 24 |
| Cordarone, % | 9 |
| Antiplatelet, % | 8 |
| Warfarin, % | 7 |
Data are expressed as mean±SD, as absolute number of patients (% on total sample) or as median (25th–75th centile).
ABPRE, abnormal blood pressure response at exercise; ACE-I/ARB, ACE inhibitors/angiotensin receptor blockers; AT, anaerobic threshold; CP, circulatory power; CPET, cardiopulmonary exercise test; FH, family history; HR, heart rate; ICD, implantable cardioverter defibrillator; LAd, left atrial diameter; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; LVOTGmax, maximal left ventricular outflow tract gradient; MWT, maximum wall thickness; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death; VE/VCO2 slope, relation between ventilation versus carbon dioxide production; VO2, oxygen consumption; VO2/WL slope, relation between VO2 versus work load; ΔSBP, difference between peak and resting systolic blood pressures.